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Cellular senescence, the irreversible loss of replicative 
potential of somatic cells, was first described in fibro-
blasts cultured in vitro by Leonard Hayflick more than 
50 years ago. Since then, the field of cellular senes-
cence has witnessed a meteoric rise, with multiple 
studies highlighting its importance in varied physiolog-
ical contexts such as cancer, development and ageing. 
A major recent development in the senescence field 
has been the creation of mouse models which allow 
the specific elimination of senescent cells. These ge-
netic tools have allowed scientists, for the first time, to 
conduct proof-of-principle investigations into the 
causal impact of senescence during the ageing process 
and in the context of several age-related diseases. Fur-
thermore, these experiments provided the rationale 
for the development of a new class of drugs named 
“senolytics”, that can specifically kill senescent cells, 
which are now of great interest to academics and 
pharma companies alike. Non-alcoholic fatty liver dis-
ease (NAFLD) is more prevalent in the older and obese 
population and unrelated to alcohol consumption. It 
can be characterized by simple liver fat accumulation 
(steatosis) but it can progress to more severe stages 
such as non-alcoholic steatohepatitis (NASH), ad-
vanced fibrosis, cirrhosis and hepatocellular carcinoma 
(HCC). Previous studies have demonstrated that during 
ageing and NAFLD, hepatocytes accumulate markers of 
cellular senescence. However, until now, it was unclear 
whether senescence was a cause or consequence of 
liver disease. 
 
In a study recently published in the journal Nature Com-
munications we have researched the role of cellular senes-
cence during liver ageing, in obesity and NAFLD. We ob-
served that hepatocyte fat accumulation occurred in paral-
lel with markers of cellular senescence in mice exposed to 
different dietary regimes and in human patients with dif-
ferent severities of non-alcoholic fatty liver disease. This 
initial observation led us to postulate that hepatic steatosis 
may be a consequence of hepatocyte senescence. 
To investigate this hypothesis, we first utilised the Ink-
ATTAC mouse model, in which a small molecule AP20187 
can induce apoptosis in p16Ink4a-postive cells, thereby elim-
inating them from tissues. We found that drug-induced 
elimination of p16Ink4a-senescent cells in both aged and 
high-fat fed Ink-ATTAC mice resulted in a significant reduc-
tion in liver fat accumulation. Secondly, we investigated 
the potential role of senolytic drugs as a therapy against 
liver steatosis. We found that treatment with a senolytic 
cocktail of dasatinib and quercetin (D+Q) significantly re-
duced liver fat accumulation in aged wild-type mice and in 
obese mice (db/db), which carry a mutation in the leptin 
receptor (Figure 1). 
It remains a possibility that the observed reduction in 
liver fat is the result of non-cell autonomous effects, since 
none of the previously described interventions is specifical-
ly targeting senescent hepatocytes. In fact, previous stud-
ies using both Ink-ATTAC mice and senolytic drugs have 
shown that drug-induced elimination of senescent cells 
occurs simultaneously in multiple tissues and ameliorates 
multiple ageing phenotypes. Thus, it is reasonable to as-
sume that reduced liver fat accumulation may be partially 
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In order to  investigate  this  further, we used  a  mouse  
model in which senescence can be induced specifically in 
hepatocytes via inactivation of the DNA repair gene Xpg. 
We found that hepatocytes lacking Xpg exhibited increased 
senescent markers as well as increased fat accumulation. 
These data support the hypothesis that cell senescence 
results in fat accumulation in a cell autonomous fashion. 
Mechanistically it is still unclear why senescent hepato-
cytes accumulate fat. Previous data suggests that factors 
such as high fat diet, increased lipid synthesis or decreased 
lipid catabolism may contribute to steatosis during NAFLD. 
Hepatic fat accumulation may promote the progression of 
NAFLD to more severe stages by promoting inflammation, 
fibrosis and cell death.   
Data from our group and others have shown that senes-
cent cells have dysfunctional mitochondria, characterized 
by impaired oxidative phosphorylation and increased gen-
eration of Reactive Oxygen Species (ROS). In fact, recent 
data indicates that mitochondria are an integral part of the 
senescence program, since ablation of mitochondria allevi-
ates many of the senescent phenotypes. 
Since mitochondria are the major sites of fatty acid oxi-
dation, we proposed that impaired fatty acid oxidation 
during senescence could explain fat accumulation. Con-
sistent with this hypothesis, we found that mitochondria 
from senescent fibroblasts and hepatocytes were less effi-
cient in metabolizing the fatty acid palmitate and were 
insensitive to inhibition of fatty acid oxidation by etomoxir 
when compared to young cells (Figure 2). 
While our study indicates that excessive fat accumula-
tion is a consequence of hepatocyte senescence, it does 
not answer why hepatocyte senescence is induced in the 
first place. Telomere damage, increased fatty acids, mito-
chondrial dysfunction and chronic inflammation are asso-
ciated with ageing, obesity and liver disease and have been 
shown to induce cellular senescence in vitro and in vivo. 
Furthermore, all these factors have been shown to be 
modulated by dietary interventions known to impact on 
hepatic steatosis. Given the complexity and interconnected 
nature of these processes we speculate that it is unlikely 
that one single mechanism is driving hepatocyte senes-
cence and that probably a combination of multiple factors 
is at play. 
In conclusion, ageing and obesity are major risk factors 
for a variety of age-related disease including NAFLD. Our 
study demonstrates that cellular senescence is a major 
driver of hepatic steatosis. Furthermore, it highlights that 
elimination of senescent cells may be a novel therapeutic 
strategy to reduce steatosis, thereby ameliorating the pro-
gression of NAFLD. 
In summary, we have revealed a strong association be-
tween cellular senescence and liver fat accumulation. Die-
tary restriction (DR) decreased numbers of senescent cells 
in parallel to strong inhibition of liver fat accumulation or 
even fat reduction. Using genetic and drug interventions 
we were further able to replicate some beneficial effects of 
DR on liver fat storage. The novelty of our approach is 
however not in inhibiting accumulation of senescent cells, 
but in alleviating liver steatosis through direct elimination 
of senescent cells that have already accumulated. As we 
took only the first step in understanding the mechanistic 
basics, it is to future research to elucidate other aspects of 
this phenomenon. 
 
Figure 1: Treatment scheme for obese and ageing 
animals. (A) db/db mice were treated with D+Q for 
2 months until 6 months of age. (B) Wild-type mice 
underwent several dietary restriction regimes. (C) 
Ink-ATTAC mice under high fat diet were treated 
with AP20187 for 4 months and (D) ageing Ink-
ATTAC mice were treated for 3 months wit AP20187 
or D+Q. 
Figure 2: Impaired fatty acid oxidation in senescent cells leads 
to increased fat storage. Induction of cellular senescence induc-
es mitochondrial dysfunction and impaired fatty acid oxidation, 
thus contributing to increased cytosolic fat accumulation (lipid 
droplets). 
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